Literature DB >> 19021405

Fibroblast autofluorescence in connective tissue disorders: a future tool for clinical and differential diagnosis?

Monica Monici1, Venere Basile, Giovanni Romano, Lucia Evangelisti, Laura Lucarini, Monica Attanasio, Enrico Bertini, Franco Fusi, Gian Franco Gensini, Guglielmina Pepe.   

Abstract

Marfan syndrome (MFS) is an inherited disorder of connective tissue due to mutations in FBN1 (90%) and TGFBR1 and TGFBR2 (5 to 10%) genes. Clinical and differential diagnosis is difficult because of the inter- and intrafamiliar marked heterogeneity and the variable onset age of clinical manifestations. Among the disorders, in differential diagnosis, thoracic aortic aneurysm (TAA) and Ullrich scleroatonic muscular dystrophy (UCMD) are reported. We evaluate the possibility of utilizing autofluorescence (AF) analysis as a diagnostic tool in the clinical and/or differential diagnosis of MFS and related disorders and in the investigation of the molecular mechanisms involved. Both multispectral imaging autofluorescence microscopy (MIAM) and autofluorescence microspectroscopy (AMS) have been used to characterize AF emission of fibroblasts from patients affected by inherited connective tissue disorders. Our preliminary results show significant differences in AF emission between normal and pathological fibroblasts, suggesting possible improvement in diagnostics of connective tissue disorders by AF analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19021405     DOI: 10.1117/1.2982533

Source DB:  PubMed          Journal:  J Biomed Opt        ISSN: 1083-3668            Impact factor:   3.170


  2 in total

1.  Differentiation of malignant B-lymphoma cells from normal and activated T-cell populations by their intrinsic autofluorescence.

Authors:  Seth M Pantanelli; Zhuqing Li; Robert Fariss; Sankaranarayana P Mahesh; Baoying Liu; Robert B Nussenblatt
Journal:  Cancer Res       Date:  2009-05-19       Impact factor: 12.701

2.  Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17.

Authors:  Quirijn R J G Tummers; Charlotte E S Hoogstins; Katja N Gaarenstroom; Cor D de Kroon; Mariette I E van Poelgeest; Jaap Vuyk; Tjalling Bosse; Vincent T H B M Smit; Cornelis J H van de Velde; Adam F Cohen; Philip S Low; Jacobus Burggraaf; Alexander L Vahrmeijer
Journal:  Oncotarget       Date:  2016-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.